Matthew Deek
Overview
Explore the profile of Matthew Deek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
416
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cao Y, Sutera P, Mendes W, Yousefi B, Hrinivich T, Deek M, et al.
Radiother Oncol
. 2024 Aug;
199:110443.
PMID: 39094629
Purpose: This study investigated imaging biomarkers derived from PSMA-PET acquired pre- and post-metastasis-directed therapy (MDT) to predict 2-year metastasis-free survival (MFS), which provides valuable early response assessment to improve patient...
2.
Sutera P, Shetty A, Song Y, Hodges T, Hoang T, Rana Z, et al.
Eur Urol Oncol
. 2023 Aug;
7(2):241-247.
PMID: 37558543
Background: Standard of care management for synchronous metastatic castration-sensitive prostate cancer (mCSPC) includes androgen deprivation therapy with a second-generation antiandrogen therapy and/or docetaxel. Recently, randomized data have demonstrated that prostate-directed...
3.
Sherwani Z, Parikh S, Yegya-Raman N, McKenna K, Deek M, Jabbour S, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444636
Historically, the role of radiation in gynecological metastatic disease involved palliation for pain or bleeding. Stereotactic Body Radiation Therapy (SBRT) has shown survival benefits in oligometastatic disease from varying primary...
4.
Sutera P, Song Y, Van der Eecken K, Shetty A, English K, Hodges T, et al.
Eur Urol
. 2023 May;
84(6):531-535.
PMID: 37173210
In metastatic castration-sensitive prostate cancer (mCSPC), disease volume plays an integral role in guiding treatment recommendations, including selection of docetaxel therapy, metastasis-directed therapy, and radiation to the prostate. Although there...
5.
Sutera P, Phillips R, Deek M, Ozyigit G, Onal C, Tran P
J Nucl Med
. 2022 Jan;
63(3):339-341.
PMID: 35058322
No abstract available.
6.
Deek M, Lilleby W, Vaage V, Hole K, DeWeese T, Stensvold A, et al.
Prostate
. 2020 Dec;
80(15):1322-1327.
PMID: 33258482
Background: Dose escalated radiation therapy (RT) combined with long-term androgen deprivation therapy (ADT) is a standard of care option for men with high-risk and locally advanced prostate cancer (PCa). However,...
7.
Kishan A, Romero T, Alshalalfa M, Liu Y, Tran P, Nickols N, et al.
Eur Urol
. 2020 May;
78(3):327-332.
PMID: 32461072
Gleason grade group (GG) 5 prostate cancer has been associated with an aggressive natural history, and retrospective data support a role for treatment intensification. However, clinical outcomes remain heterogeneous in...
8.
Phillips R, Shi W, Deek M, Radwan N, Lim S, Antonarakis E, et al.
JAMA Oncol
. 2020 Mar;
6(5):650-659.
PMID: 32215577
Importance: Complete metastatic ablation of oligometastatic prostate cancer may provide an alternative to early initiation of androgen deprivation therapy (ADT). Objective: To determine if stereotactic ablative radiotherapy (SABR) improves oncologic...
9.
David J, Gresham G, Jabbour S, Deek M, Thomassian S, Robertson J, et al.
J Gastrointest Oncol
. 2018 Aug;
9(4):641-649.
PMID: 30151260
Background: Neoadjuvant chemoradiation (NeoCRT) is standard of care for the treatment of locally advanced rectal cancer (LARC). Contemporary radiation techniques and pre-treatment imaging may impact toxicities and pathologic response (PR)....